Kevin is the CEO and co-founder of Hyacinth Bio. Founded in 2014, Hyasynth is developing strains of yeast that have the ability to produce the active compounds of cannabis called cannabinoids. Despite the rapid growth of the medical cannabis industry, there is still limited access to products, and the quality and reliability of the current, plant-based supply chain is often poorly regulated. Patients, both young and old, need cannabinoid products that they can depend on. Hyasynth is creating a supply chain for cannabinoids that the industry can depend on, and more.
Aside from his work at Hyasynth, Kevin runs the community biology lab in Montreal called Bricobio, is a supporter and frequent judge at iGEM.